ReShape Common Stock Total Equity vs Other Stockholder Equity Analysis

RSLS Stock

USD 5.68 0.07 1.22%

ReShape Lifesciences financial indicator trend analysis is much more than just breaking down ReShape Lifesciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ReShape Lifesciences is a good investment. Please check the relationship between ReShape Lifesciences Common Stock Total Equity and its Other Stockholder Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Common Stock Total Equity vs Other Stockholder Equity

Common Stock Total Equity vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ReShape Lifesciences Common Stock Total Equity account and Other Stockholder Equity. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between ReShape Lifesciences' Common Stock Total Equity and Other Stockholder Equity is -0.43. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of ReShape Lifesciences, assuming nothing else is changed. The correlation between historical values of ReShape Lifesciences' Common Stock Total Equity and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of ReShape Lifesciences are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Common Stock Total Equity i.e., ReShape Lifesciences' Common Stock Total Equity and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

-0.43

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Other Stockholder Equity

Most indicators from ReShape Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.20 in 2024, whereas Tax Provision is likely to drop (36.8 K) in 2024.

ReShape Lifesciences fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Short Term Debt
Total Assets		0.97	-0.13	0.73	-0.03	0.34	0.57	0.08	-0.36	0.15	0.23	-0.3	0.34	0.21	0.92	0.37	-0.18	0.21	0.25	0.12	0.44	0.04	0.17	-0.31	0.26	0.23
Total Stockholder Equity	0.97		-0.13	0.8	-0.09	0.31	0.37	-0.06	-0.47	0.0	0.21	-0.32	0.27	0.21	0.9	0.42	-0.19	0.2	0.19	0.09	0.34	0.02	0.15	-0.23	0.26	0.18
Retained Earnings	-0.13	-0.13		0.08	0.38	-0.91	-0.08	0.4	-0.06	-0.39	-0.31	-0.22	-0.69	0.47	-0.17	0.25	-0.5	0.48	-0.73	0.52	0.43	-0.04	-0.4	0.51	0.19	0.28
Other Assets	0.73	0.8	0.08		-0.13	0.05	0.11	-0.23	-0.52	-0.37	-0.12	-0.08	-0.09	0.0	0.78	0.29	-0.37	-0.01	-0.14	0.16	0.44	-0.15	-0.14	-0.06	-0.03	0.0
Common Stock Shares Outstanding	-0.03	-0.09	0.38	-0.13		-0.37	0.22	0.32	0.31	-0.12	-0.04	-0.57	-0.44	0.72	-0.31	0.18	-0.05	0.72	-0.38	0.64	0.32	-0.16	-0.07	-0.17	0.66	0.22
Other Stockholder Equity	0.34	0.31	-0.91	0.05	-0.37		0.24	-0.31	0.0	0.39	0.36	0.14	0.76	-0.37	0.35	-0.1	0.4	-0.37	0.78	-0.43	-0.25	0.11	0.44	-0.51	-0.17	-0.17
Total Liab	0.57	0.37	-0.08	0.11	0.22	0.24		0.53	0.24	0.62	0.18	-0.07	0.42	0.1	0.49	0.0	-0.02	0.1	0.35	0.17	0.59	0.11	0.13	-0.41	0.11	0.26
Short Long Term Debt Total	0.08	-0.06	0.4	-0.23	0.32	-0.31	0.53		-0.15	0.31	-0.17	0.14	-0.11	0.18	0.09	-0.1	0.11	0.18	-0.17	0.18	0.54	-0.08	-0.23	0.25	0.03	0.68
Other Current Liab	-0.36	-0.47	-0.06	-0.52	0.31	0.0	0.24	-0.15		0.42	0.45	-0.31	0.2	0.22	-0.52	-0.22	0.17	0.22	0.25	0.12	-0.12	0.05	0.46	-0.22	0.29	-0.53
Total Current Liabilities	0.15	0.0	-0.39	-0.37	-0.12	0.39	0.62	0.31	0.42		0.41	0.02	0.62	-0.05	0.09	-0.36	0.44	-0.04	0.62	-0.34	-0.15	0.09	0.41	-0.25	0.11	-0.04
Property Plant And Equipment Net	0.23	0.21	-0.31	-0.12	-0.04	0.36	0.18	-0.17	0.45	0.41		-0.47	0.57	0.31	0.06	0.11	0.55	0.31	0.58	-0.18	-0.08	-0.08	0.98	0.03	0.48	-0.49
Net Debt	-0.3	-0.32	-0.22	-0.08	-0.57	0.14	-0.07	0.14	-0.31	0.02	-0.47		0.2	-0.92	0.08	-0.5	0.06	-0.93	0.19	-0.49	0.05	0.08	-0.4	0.23	-0.95	0.07
Accounts Payable	0.34	0.27	-0.69	-0.09	-0.44	0.76	0.42	-0.11	0.2	0.62	0.57	0.2		-0.38	0.4	-0.19	0.39	-0.38	0.96	-0.57	-0.09	0.34	0.56	-0.21	-0.18	-0.3
Cash	0.21	0.21	0.47	0.0	0.72	-0.37	0.1	0.18	0.22	-0.05	0.31	-0.92	-0.38		-0.16	0.47	-0.07	1.0	-0.36	0.6	0.11	-0.16	0.24	-0.03	0.94	0.15
Non Current Assets Total	0.92	0.9	-0.17	0.78	-0.31	0.35	0.49	0.09	-0.52	0.09	0.06	0.08	0.4	-0.16		0.19	-0.19	-0.16	0.3	-0.08	0.49	0.06	0.02	-0.14	-0.12	0.21
Non Currrent Assets Other	0.37	0.42	0.25	0.29	0.18	-0.1	0.0	-0.1	-0.22	-0.36	0.11	-0.5	-0.19	0.47	0.19		-0.43	0.45	-0.31	0.4	0.09	0.36	0.02	-0.3	0.37	0.27
Long Term Debt	-0.18	-0.19	-0.5	-0.37	-0.05	0.4	-0.02	0.11	0.17	0.44	0.55	0.06	0.39	-0.07	-0.19	-0.43		-0.07	0.45	-0.49	-0.24	-0.34	0.61	0.21	0.12	-0.31
Cash And Short Term Investments	0.21	0.2	0.48	-0.01	0.72	-0.37	0.1	0.18	0.22	-0.04	0.31	-0.93	-0.38	1.0	-0.16	0.45	-0.07		-0.36	0.6	0.11	-0.16	0.24	-0.03	0.94	0.15
Net Receivables	0.25	0.19	-0.73	-0.14	-0.38	0.78	0.35	-0.17	0.25	0.62	0.58	0.19	0.96	-0.36	0.3	-0.31	0.45	-0.36		-0.55	-0.16	0.16	0.61	-0.19	-0.14	-0.37
Common Stock Total Equity	0.12	0.09	0.52	0.16	0.64	-0.43	0.17	0.18	0.12	-0.34	-0.18	-0.49	-0.57	0.6	-0.08	0.4	-0.49	0.6	-0.55		0.39	-0.26	-0.23	-0.22	0.45	0.35
Non Current Liabilities Total	0.44	0.34	0.43	0.44	0.32	-0.25	0.59	0.54	-0.12	-0.15	-0.08	0.05	-0.09	0.11	0.49	0.09	-0.24	0.11	-0.16	0.39		-0.15	-0.13	0.16	-0.05	0.29
Other Current Assets	0.04	0.02	-0.04	-0.15	-0.16	0.11	0.11	-0.08	0.05	0.09	-0.08	0.08	0.34	-0.16	0.06	0.36	-0.34	-0.16	0.16	-0.26	-0.15		-0.14	-0.28	-0.18	0.1
Property Plant And Equipment Gross	0.17	0.15	-0.4	-0.14	-0.07	0.44	0.13	-0.23	0.46	0.41	0.98	-0.4	0.56	0.24	0.02	0.02	0.61	0.24	0.61	-0.23	-0.13	-0.14		0.01	0.41	-0.52
Preferred Stock Total Equity	-0.31	-0.23	0.51	-0.06	-0.17	-0.51	-0.41	0.25	-0.22	-0.25	0.03	0.23	-0.21	-0.03	-0.14	-0.3	0.21	-0.03	-0.19	-0.22	0.16	-0.28	0.01		-0.16	-0.12
Total Current Assets	0.26	0.26	0.19	-0.03	0.66	-0.17	0.11	0.03	0.29	0.11	0.48	-0.95	-0.18	0.94	-0.12	0.37	0.12	0.94	-0.14	0.45	-0.05	-0.18	0.41	-0.16		0.01
Short Term Debt	0.23	0.18	0.28	0.0	0.22	-0.17	0.26	0.68	-0.53	-0.04	-0.49	0.07	-0.3	0.15	0.21	0.27	-0.31	0.15	-0.37	0.35	0.29	0.1	-0.52	-0.12	0.01

Click cells to compare fundamentals

ReShape Lifesciences Account Relationship Matchups

ReShape Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	39.7M	37.1M	54.3M	11.1M	10.7M	10.1M
Total Stockholder Equity	24.1M	14.5M	46.1M	3.7M	6.7M	6.3M
Retained Earnings	(493.2M)	(514.8M)	(576.8M)	(624.2M)	(635.6M)	(603.8M)
Other Assets	99K	46K	1.5M	102K	117.3K	111.4K
Common Stock Shares Outstanding	31.4K	26.0K	3.8K	7.3K	102.7K	128.9K
Liabilities And Stockholders Equity	39.7M	37.1M	54.3M	11.1M	10.7M	10.1M
Other Stockholder Equity	517.3M	529.4M	622.4M	627.9M	642.3M	323.4M
Total Liab	15.6M	22.6M	8.2M	7.5M	4M	3.8M
Short Long Term Debt Total	3.0M	9.5M	279K	171K	262K	248.9K
Other Current Liab	5.6M	7.2M	3.2M	5.1M	1.8M	3.3M
Total Current Liabilities	10.4M	11.6M	7.3M	7.5M	3.8M	6.0M
Property Plant And Equipment Net	774K	1.0M	1.7M	869K	310K	600.4K
Net Debt	(2.2M)	(2.5M)	(22.5M)	(3.7M)	(4.2M)	(4.4M)
Accounts Payable	4.3M	3.7M	3.5M	1.9M	1.7M	1.3M
Cash	2.9M	3.0M	22.8M	3.9M	4.5M	4.2M
Non Current Assets Total	29.5M	28.1M	24.0M	1.2M	367K	348.7K
Non Currrent Assets Other	562.9K	99K	46K	1.5M	29K	27.6K
Cash And Short Term Investments	2.9M	3.0M	22.8M	3.9M	4.5M	4.2M
Net Receivables	4.1M	2.6M	2.8M	2.2M	1.7M	997.2K
Non Current Liabilities Total	5.2M	11.0M	855K	2.6M	223K	211.9K
Other Current Assets	1.7M	1.1M	1.4M	265K	437K	415.2K
Property Plant And Equipment Gross	774K	1.0M	1.7M	1.2M	400K	618.1K
Total Current Assets	10.1M	8.9M	30.3M	9.9M	10.3M	16.2M
Accumulated Other Comprehensive Income	(8K)	(121K)	(92K)	(88K)	(79.2K)	(83.2K)
Short Term Debt	291K	314K	558K	342K	222K	210.9K
Common Stock	8K	6K	18K	1K	23K	21.9K
Property Plant Equipment	16K	584K	1.7M	869K	782.1K	565.6K
Other Liab	6.2M	4.7M	1.6M	855K	983.3K	934.1K
Current Deferred Revenue	352K	202K	398K	549K	44K	46.2K
Inventory	1.3M	2.2M	3.0M	3.6M	3.7M	3.9M
Net Tangible Assets	(4.6M)	(12.5M)	25.2M	3.4M	3.1M	4.0M
Retained Earnings Total Equity	(334.8M)	(419.0M)	(493.2M)	(514.8M)	(463.3M)	(486.5M)
Capital Surpluse	410.8M	450.6M	517.3M	529.4M	608.8M	386.1M
Deferred Long Term Liab	5.3M	1.8M	702K	615K	707.3K	929.9K
Intangible Assets	28.7M	27.0M	20.8M	260K	299K	284.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC